Arcus Biosciences, Inc. granted employment inducement awards to two new employees, consisting of options to purchase 18,400 shares and restricted stock units to acquire 9,250 shares of common stock. The options carry an exercise price of $28.18 per share, which was the closing price on June 23, 2026. These equity awards were granted pursuant to the company’s 2020 Inducement Plan.

The Compensation Committee of the Board of Directors approved the grants. The 2020 Inducement Plan was authorized by the Board in January 2020 under the "inducement exception" outlined in NYSE Listed Company Manual Rule 303A.08. This exception allows companies to issue equity awards as a material inducement to new employees without requiring shareholder approval.

Breakdown of Awards

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. The company was founded in 2015 and has advanced multiple investigational medicines into registrational clinical trials.

Arcus Biosciences granted equity awards to a new employee, consisting of options to purchase 2,850 shares and restricted stock units to acquire 1,450 shares of common stock. The options carry an exercise price of $23.32 per share, which was the closing price on June 8, 2026. These grants were made as an employment inducement under the company's 2020 Inducement Plan.

The Compensation Committee of Arcus Biosciences' Board of Directors approved the awards. The 2020 Inducement Plan was sanctioned by the Board in January 2020, utilizing the "inducement exception" outlined in NYSE Listed Company Manual Rule 303A.08. This regulatory provision allows companies to issue awards to new employees as an incentive for joining the organization.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. The company collaborates with industry partners to expedite the development of its late-stage portfolio, targeting well-characterized biological pathways.

Award Details

Founded in 2015, Arcus Biosciences has advanced multiple investigational medicines into registrational clinical trials. Key candidates include casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer.